CD47 and B-cell non-Hodgkin lymphoma: Summary of percentage increase in phagocytosis of CD20+ B-cell lymphoma cells (Granta-519) induced by tumor-specific mAb (anti-CD20 RTX, anti-CD59, or anti-PD-L1) in combination with RTX-IgG2 or anti-CD47 mAb (where applicable) in comparison with single use of tumor-specific mAb.